Clinicians should not screen men who do not express a preference for screening and should not routinely screen men 70 years and older. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes, and other health needs. Harms are greater for men 70 years and older. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy overdiagnosis and overtreatment and treatment complications, such as incontinence and erectile dysfunction. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. The decision to be screened for prostate cancer should be an individual one.īefore deciding whether to be screened, men aged 55 to 69 years should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older. Clinicians should not screen men who do not express a preference for screening. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one.

Mark 23 and usp difference